JPM vs MKL
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
MKL presents a stark disconnect between fundamental value and market momentum, characterized by a stable Piotroski F-Score of 4/9 and a current price significantly below its Graham Number ($2143.77) and Intrinsic Value ($4078.97). While the company maintains a very healthy balance sheet with low debt/equity (0.26) and strong liquidity, it is currently plagued by a 0/100 technical trend and bearish insider sentiment. Recent quarterly performance is concerning, with Q/Q revenue growth at -13.50% and a sharp Q/Q EPS decline of -37.0%. Consequently, while the long-term value proposition is strong, the short-term trajectory is bearish.
Compare Another Pair
Related Comparisons
JPM vs MKL: Head-to-Head Comparison
This page compares JPMorgan Chase & Co. (JPM) and Markel Group Inc. (MKL) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.